Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.

Bosnian journal of basic medical sciences - 23 Oct 2022

Topcu Atakan, Ozturk Akin, Yurtsever Ismail, Besiroglu Mehmet, Yasin Ayse Irem, Turk Haci Mehmet, Seker Mesut

Abstract excerpt

Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to C-Reactive Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Protein Kinase Inhibitors

Share to Sarcopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 35575465
DOI: 10.17305/bjbms.2022.7147
PMCID: PMC9589317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.PMID 35575465Read ↗

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?Semantic proximity Read ↗

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib.Semantic proximity Read ↗

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase InhibitorsSemantic proximity Read ↗

The Impact of Sarcopenia on Overall Survival in Patients with Pan-RAS Wild-type Colorectal Liver Metastasis Receiving HepatectomySemantic proximity Read ↗

Independent and joint association of sarcopenia and frailty with mortality in older patients with gastrointestinal cancer: A cohort study with prospective data collectionSemantic proximity Read ↗

Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.Semantic proximity Read ↗

Could Sarcopenia be Related to Chemotherapy in Gastrointestinal Cancer? A Cross-Sectional Study Including Comprehensive Geriatric AssessmentSemantic proximity Read ↗

Shared and Divergent Epigenetic Mechanisms in Cachexia and SarcopeniaSemantic proximity Read ↗

An Overview of Sarcopenia: Focusing on Nutritional Treatment ApproachesSemantic proximity Read ↗

Development and Validation of a Clinically Useful Nomogram for Predicting Sarcopenia in Bone Tumor PatientsSemantic proximity Read ↗

Primary tumor location is a risk factor for postoperative development of sarcopenia related to poor outcomes in patients with colorectal cancerSemantic proximity Read ↗

Identification of microRNAs in skeletal muscle associated with lung cancer cachexiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.